Lead party: Laprophan S.A (lead investor/buyer)
Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed).
Target: Amanys Pharma (private company) · Sector: Healthcare, Pharmaceuticals · Countries of operation: Morocco
Transaction type: Merger/Acquisition(M&A), Exit · Asset class: Private Equity, Corporate Transactions · Strategy: Bolt-On · Fund: SPE Africa Industrialisation Fund I
Lead investor/buyer: Laprophan S.A · Investors/buyers: Laprophan S.A · Sellers: SPE Capital Partners, Proparco
Legal advisers: not identified in the source record.
Source: announced 11 November 2023. Original announcement: spe-capital.com.


